Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Mesothelioma 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 9Hyperthermic Intraperitoneal Chemotherapy 3fludarabine 2budigalimab 2Nivolumab 2Ipilimumab 2Cytoreduction Surgical Procedures 2Cyclophosphamide 2Cisplatin 2venetoclax 1tocilizumab 1tislelizumab 1talazoparib 1spartalizumab 1sodium thiosulfate 1rovalpituzumab tesirine 1regorafenib 1milademetan 1irinotecan sucrosofate 1fludarabine phosphate 1epacadostat 1entinostat 1atezolizumab 1X-Rays 1Surgical Procedures, Operative 1Specimen Handling 1Sirolimus 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × milademetan × Other solid neoplasm × Clear all
NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

Phase 1/2 Withdrawn
DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡